Medical Aesthetics: A Rising Tide Lifts All Ships In A Booming Market With Room For Growth
Major players in medical aesthetics are investing in the overall growth of the market in the hope that a rising tide will lift all ships. Research shows that while millions have tried facial injectables and other non-invasive treatments, many more need one last push into the dermatologist's office.
You may also be interested in...
The only addition to AbbVie’s leadership after it closes the $63bn acquisition of Allergan will be Carrie Strom, who will lead the Allergan Aesthetics business.
Detailed data presented at Digestive Disease Week show competitive efficacy in ulcerative colitis and a potential best-in-class safety profile for the S1P receptor modulator Pfizer acquired earlier this year.
With the sale of its migraine portfolio to Pfizer pending, Biohaven said troriluzole – a lead asset in the pipeline soon to be spun out in a new company – failed in a Phase III trial.